AbCellera Biologics annual r&d spending
2019
2020
2021
2022
2023
2024
2025
AbCellera Biologics R&D Spending Growth & History (ABCL)
AbCellera Biologics's r&d spending was $186.8M for fiscal 2025.
View full AbCellera Biologics company overviewAbCellera Biologics annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $186.8M | $19.6M | +11.70% |
| 2024 | 2024-12-31 | $167.3M | −$8.4M | −4.78% |
| 2023 | 2023-12-31 | $175.7M | $67.8M | +62.83% |
| 2022 | 2022-12-31 | $107.9M | $45.8M | +73.82% |
| 2021 | 2021-12-31 | $62.1M | $32.7M | +111.15% |
| 2020 | 2020-12-31 | $29.4M | $19.3M | +190.65% |
| 2019 | 2019-12-31 | $10.1M | — | — |
AbCellera Biologics quarterly r&d spending
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $46.0M | $6.8M | +17.27% |
| Q1 2026 | 2026-03-31 | $46.7M | $4.2M | +9.80% |
| Q4 2025 | 2025-12-31 | $50.1M | $4.0M | +8.72% |
| Q3 2025 | 2025-09-30 | $55.0M | $14.1M | +34.32% |
| Q2 2025 | 2025-06-30 | $39.2M | −$1.7M | −4.19% |
| Q1 2025 | 2025-03-31 | $42.5M | $3.2M | +8.17% |
| Q4 2024 | 2024-12-31 | $46.1M | −$2.5M | −5.23% |
| Q3 2024 | 2024-09-30 | $41.0M | $3.1M | +8.05% |
| Q2 2024 | 2024-06-30 | $40.9M | $4.5M | +12.21% |
| Q1 2024 | 2024-03-31 | $39.3M | −$13.4M | −25.38% |
| Q4 2023 | 2023-12-31 | $48.6M | $20.4M | +72.13% |
| Q3 2023 | 2023-09-30 | $37.9M | $11.3M | +42.64% |
| Q2 2023 | 2023-06-30 | $36.5M | $9.8M | +36.68% |
| Q1 2023 | 2023-03-31 | $52.6M | $26.3M | +99.68% |
| Q4 2022 | 2022-12-31 | $28.2M | $11.0M | +64.09% |
| Q3 2022 | 2022-09-30 | $26.6M | $9.1M | +52.33% |
| Q2 2022 | 2022-06-30 | $26.7M | $11.6M | +77.36% |
| Q1 2022 | 2022-03-31 | $26.4M | $14.0M | +113.46% |
| Q4 2021 | 2021-12-31 | $17.2M | $8.6M | +99.33% |
| Q3 2021 | 2021-09-30 | $17.4M | $10.0M | +132.82% |
| Q2 2021 | 2021-06-30 | $15.0M | $5.9M | +64.55% |
| Q1 2021 | 2021-03-31 | $12.4M | $8.2M | +199.95% |
| Q4 2020 | 2020-12-31 | $8.6M | — | — |
| Q3 2020 | 2020-09-30 | $7.5M | — | — |
| Q2 2020 | 2020-06-30 | $9.1M | — | — |
| Q1 2020 | 2020-03-31 | $4.1M | — | — |
AbCellera Biologics r&d spending trends
Over the last five fiscal years, AbCellera Biologics's r&d spending increased from $29.4M to $186.8M, a change of $157.4M. The latest reported quarter, Q2 2026, shows $46.0M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review AbCellera Biologics source filings ↗